EP4200274A2 - Compositions d'acide bêta-hydroxybutyrique et procédés d'administration orale de corps cétoniques - Google Patents

Compositions d'acide bêta-hydroxybutyrique et procédés d'administration orale de corps cétoniques

Info

Publication number
EP4200274A2
EP4200274A2 EP21859286.3A EP21859286A EP4200274A2 EP 4200274 A2 EP4200274 A2 EP 4200274A2 EP 21859286 A EP21859286 A EP 21859286A EP 4200274 A2 EP4200274 A2 EP 4200274A2
Authority
EP
European Patent Office
Prior art keywords
beta
hydroxybutyric acid
composition
aqueous
hydroxybutyrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21859286.3A
Other languages
German (de)
English (en)
Other versions
EP4200274A4 (fr
Inventor
Gary MILLET
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axcess Global Sciences LLC
Original Assignee
Axcess Global Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/996,509 external-priority patent/US10973786B2/en
Priority claimed from US17/210,646 external-priority patent/US11806324B2/en
Application filed by Axcess Global Sciences LLC filed Critical Axcess Global Sciences LLC
Publication of EP4200274A2 publication Critical patent/EP4200274A2/fr
Publication of EP4200274A4 publication Critical patent/EP4200274A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention relates to aqueous drinks, liquid and powder drink additives, and liquid and powder food additives containing beta-hydroxybutyric acid and methods for delivering exogenous ketone bodies to a subject in need thereof.
  • Ketone bodies can be used by cells of the body as fuel to satisfy the body’s energy needs.
  • blood ketone levels can increase to 2-3 mmol/L or more. It is conventionally understood that when blood ketones rise above 0.5 mmol/L, the heart, brain, and peripheral tissues use ketone bodies (e.g., beta-hydroxybutyrate and acetoacetate) as the primary fuel source. This condition is referred to as “ketosis”.
  • ketosis Between 1.0 mmol/L and 3.0 mmol/L the condition is called “nutritional ketosis.” [0003] Upon transitioning into ketosis, i.e., during ketogenic metabolism in the liver, the body uses dietary and bodily fats as a primary energy source. Consequently, when in ketosis, one can induce loss of body fat by controlling dietary fat intake and maintaining low carbohydrate intake and blood level to sustain ketosis.
  • ketosis While in ketosis, the body is in ketogenesis and is essentially burning fat for its primary fuel.
  • the body cleaves fats into fatty acids and glycerol and transforms fatty acids into acetyl CoA molecules, which are transformed through ketogenesis into the water-soluble ketone bodies beta-hydroxybutyrate (“p-hydroxybutyrate” or “beta- hydroxybutyrate”), acetoacetate, and acetone in the liver.
  • beta-hydroxybutyrate and acetoacetate are used by the body for energy, while acetone is removed as a by-product of ketogenesis.
  • ketone bodies The metabolism of ketone bodies is associated with several improvements to metabolic function, such as anticonvulsant effects, enhanced metabolism by the brain, neuroprotection, muscle sparing properties, improved cognitive and physical performance, and epigenetic effects (positive or beneficial gene expressions).
  • Science- based improvements in efficiency of cellular metabolism, managed through ketone supplementation, can have beneficial impacts on physical, cognitive health, and psychological health, and a long-term impact on health with respect to the common avoidable diseases such as obesity, cardiovascular disease, neurodegenerative diseases, diabetes, and cancer.
  • Ketone bodies are most often administered as salts or esters. Ketone salts are generally safe but can introduce excessive quantities of electrolytes when consumed in excess. Ketone esters do not contribute electrolytes but must be hydrolyzed before they are usable as ketone bodies. Downsides of ketone esters is they can have unpleasant taste and introduce alcohol into the body when hydrolyzed.
  • beta-hydroxybutyrate Free acid forms of beta-hydroxybutyrate and acetoacetate are used less frequently, ft has been reported that solutions of racemic beta-hydroxybutyric acid have been administered intravenously. Dilute solutions are required when ketone body acids are delivered intravenously to prevent negative effects of low pH and isotonic deficiency. For example, a 1 mmol/L beta-hydroxybutyric acid solution contains only
  • compositions containing beta-hydroxybutyric acid and beta- hydroxybutyrate salt in ratios of up to “ ⁇ 125 parts free acid per ⁇ 7 parts salt” (paragraph [0019]), which equates to a free acid concentration of up to about 94.7% by weight and a salt concentration of at least about 5.3% by weight.
  • aqueous beta-hydroxybutyric acid compositions for oral delivery that are free or substantially free of beta- hydroxybutyrate salts are effective in rapidly raising blood ketone levels without causing acute acidosis or gastrointestinal (GI) distress when consumed in sufficiently dilute form.
  • aqueous beta-hydroxybutyric acid solutions can deliver exogenous ketone bodies without significantly altering electrolyte balance.
  • aqueous beta-hydroxybutyric acid solutions can have a concentration that is sufficiently diluted such that volumes of about 4 oz. (about 120 ml) to about 16 oz. (about 475 ml) can deliver a quantity of ketone bodies in a range of about 0.5 gram to about 25 grams, without harming the stomach or causing significant acidosis.
  • dilute aqueous beta-hydroxybutyric acid solutions can have a concentration of beta-hydroxybutyric acid in a range of about 0.4% w/v to about 6% w/v.
  • aqueous beta-hydroxybutyric acid solutions are moderately acidic, with a pH of about 3.5 to 4, when diluted with sufficient water, the water itself acts as a pseudo buffering agent that offsets the otherwise harsh effects of the acid 'when consumed orally.
  • aqueous beta-hydroxybutyric acid solutions can be provided as a concentrate for later dilution by the user, such as with water, juice, drink, energy shot, or other aqueous composition to a concentration in a range of about 0.4% w/v to about 6% w/v.
  • Concentrated solutions may comprise beta-hydroxybutyric acid in a range of about 6% w/v to about 60% w/v and then diluted by the user as desired, such as from about 2 to about 30 times, with water, juice, drink, or other aqueous composition, as desired.
  • the aqueous beta-hydroxybutyric acid solutions will not be so concentrated so as to self-polymerize and form significant amounts of precipitates, although it should be understood that such polymerized precipitates are harmless when consumed with sufficient water but lack the efficacy of the monomeric form of beta-hydroxybutyric acid.
  • concentrated or dilute beta-hydroxybutyric acid solutions can be manufactured by combining a powder or other solid form of beta- hydroxybutyric acid with water, drink, beverage, sauce, gel, or other liquid or semiliquid drink, energy product, or food product.
  • the powder or other solid form of beta-hydroxybutyric acid can be flavored and may contain other additives, such as one or more of stabilizer, vitamin, mineral, stimulant, nootropic, vasodilator, cannabinoid, amino acid, and the like.
  • the powder may be provided in individual pre-dosed packets, pouches, tablets, or capsules, or it may be provided in a kit with a measuring device configured to measure out a predetermined dose or fraction thereof.
  • a plurality (e.g., 2 or 3) of dissolvable tablets representing a single dose can be packaged together in a packet, pouch, or other container.
  • a dissolvable tablet may be effervescent and fizz when added to water.
  • an effervescent tablet it may be desirable to include a quantity of an edible acid (e.g., citric or malic) together with a bicarbonate or carbonate salt to provide the desired effervescent action yet provide less than 1% of total beta-hydroxybutyrate salt(s) upon dissolution in water (i.e., if the edible acid has a lower pKa than beta-hydroxybutyric acid a salt of the edible acid will form preferentially over beta-hydroxybutyrate salt).
  • an edible acid e.g., citric or malic
  • Beta-hydroxybutyric acid compositions are free or substantially free of beta- hydroxybutyrate salts so as to contain less than 1% of one or more beta- hydroxybutyrate salts by combined weight of beta-hydroxybutyric acid and beta- hydroxybutyrate salt(s).
  • beta-hydroxybutyric acid compositions are essentially or totally free of beta-hydroxybutyrate salts, i.e., contain 0% by weight of beta-hydroxybutyrate salts.
  • the beta-hydroxybutyric acid compositions may contain one or more nutritionally or pharmaceutically acceptable carriers or additives in addition to water.
  • beta-hydroxybutyric acid compositions may optionally include at least one additive selected from acetoacetic acid, 1,3 -butanediol, beta- hydroxybutyrate esters, vitamins, minerals, central nervous system stimulants, nootropics, edible acids, amino acids, muscle-promoting compounds (e.g., betahydroxy beta-methylbutyrate), one or more cannabinoids (e.g., tetrahydrocannabinol and/or cannabidiol), and the like.
  • at least one additive selected from acetoacetic acid, 1,3 -butanediol, beta- hydroxybutyrate esters, vitamins, minerals, central nervous system stimulants, nootropics, edible acids, amino acids, muscle-promoting compounds (e.g., betahydroxy beta-methylbutyrate), one or more cannabinoids (e.g., tetrahydrocannabinol and/or cannabidiol), and the like.
  • beta-hydroxybutyric acid compositions may include enantiomerically pure R-beta-hydroxybutyric acid, enantiomerically pure S- beta-hydroxybutyric acid, a racemic mixture of R- and S-beta-hydroxybutyric acid (i.e., a mixture having a 1 : 1 enantiomeric ratio of R-beta-hydroxybutyric acid and S-beta- hydroxybutyric acid), a non-racemic mixture enriched with the R-enantiomer, or a non- racemic mixture enriched with the S-enantiomer.
  • beta-hydroxybutyric acid compositions contain a non-racemic mixture enriched with the R-enantiomer, such as greater than 50% and less than 100% by enantiomeric equivalents of exogenous R-beta-hydroxybutyric acid and less than 50% and greater than 0% by enantiomeric equivalents of exogenous S- beta-hydroxybutyric acid.
  • beta-hydroxybutyric acid compositions contain a non-racemic mixture enriched with the S-enantiomer, such as greater than 50% and less than 100% by enantiomeric equivalents of exogenous S-beta-hydroxybutyric acid and less than 50% and greater than 0% by enantiomeric equivalents of exogenous R-beta- hydroxybutyric acid.
  • beta-hydroxybutyric acid compositions contain a racemic mixture of R-beta-hydroxybutyric acid and S-beta-hydroxybutyric acid, i.e., that contains 50% by enantiomeric equivalents of exogenous R-beta-hydroxybutyric acid and 50% by enantiomeric equivalents of exogenous S-beta-hydroxybutyric acid.
  • beta-hydroxybutyric acid compositions contain enantiomerically pure S-beta-hydroxybutyric acid, i.e., that contains 100% by enantiomeric equivalents of exogenous S-beta-hydroxybutyric acid and 0% by enantiomeric equivalents of R-beta-hydroxybutyric acid.
  • beta-hydroxybutyric acid compositions contain enantiomerically pure R-beta-hydroxybutyric acid, i.e., that contains 100% by enantiomeric equivalents of exogenous R-beta-hydroxybutyric acid and 0% by enantiomeric equivalents of S-beta-hydroxybutyric acid.
  • R-beta-hydroxybutyric acid i.e., that contains 100% by enantiomeric equivalents of exogenous R-beta-hydroxybutyric acid and 0% by enantiomeric equivalents of S-beta-hydroxybutyric acid.
  • beta-hydroxybutyric acid At biological pH, the endogenous form of beta-hydroxybutyric acid only exists as substantially deprotonated R-beta- hydroxybutyrate anions and not as a powder, solid, concentrated solution, or even dilute R-beta-hydroxybutyric acid solution within the disclosed concentrations.
  • S-beta-hydroxybutyric acid which is not endogenously produced by mammals and is believed by some to be unnatural and potentially harmful, can provide other beneficial effects. These include one or more of: increased endogenous production of R-beta-hydroxybutyrate and acetoacetate; endogenous conversion into one or both of R-beta-hydroxybutyrate and acetoacetate; endogenous conversion into fatty acids and sterols; prolonged ketosis; metabolism of S-beta-hydroxybutyrate independent of its conversion to R-beta- hydroxybutyrate and/or acetoacetate; improved fetal development; increased growth years; reduced endogenous production of acetone during ketosis; signaling to modulate metabolism of R-beta-hydroxybutyrate and glucose; antioxidant activity; and production of acetyl-CoA.
  • Beta-hydroxybutyric acid compositions that are enriched with, or contain enantiomerically pure, S -beta-hydroxybutyric acid may be administered in higher doses than compositions enriched with, or that contain enantiomerically pure, R-beta- hydroxybutyric acid to obtain the same rapid supply of R-beta-hydroxybutyrate in the body.
  • Beta-hydroxybutyric acid compositions disclosed herein may function to induce and/or sustain ketosis in a subject to which the composition is administered without significantly affecting electrolyte balance. This removes an otherwise limiting factor as to how much beta-hydroxybutyrate can be administered when administered in salt form.
  • beta-hydroxy butyrate esters particularly by themselves or when the primary source of beta-hydroxybutyrate, have an unpleasant taste and are not always well tolerated.
  • Beta-hydroxybutyric acid compositions can be useful as a weight loss supplement, as treatment for high blood glucose or type II diabetes, as brain tonic, as athletic performance enhancer, as preventative against metabolic dysfunction, mitochondrial defect, insulin resistance, as adjunct to a ketogenic diet, as anti-aging supplement, and for other uses associated with improved metabolic health.
  • Beta-hydroxybutyric acid compositions can be used in a method for increasing ketone body level in a subject in need thereof, including promoting and/or sustaining ketosis in the subject, comprising administering to the subject a nutritionally or pharmaceutically effective amount of beta-hydroxybutyric acid.
  • Benefits of increased ketone body level in a subject include one or more of appetite suppression, weight loss, fat loss, reduced blood glucose level, improved mental alertness, increased physical energy, improved cognitive function, reduction in traumatic brain injury, reduction in effect of diabetes, improvement of neurological disorder, reduction of cancer, reduction of inflammation, anti-aging, antiglycation, reduction in epileptic seizer, improved mood, increased strength, increased muscle mass, or improved body composition.
  • beta-hydroxybutyric acid compositions for oral delivery and methods for their delivery, such as to increase ketone body level in a subject, including to promote and/or sustain ketosis in a subject while not affecting electrolytic balance and without causing acute acidosis or gastrointestinal (GI) distress.
  • the beta-hydroxybutyric acid compositions are typically administered as an aqueous composition, suspension, or gel. Powder or solid beta-hydroxybutyric acid can be mixed with water, aqueous liquid, other liquid, gel, or food to form a solution containing beta-hydroxybutyric acid as a solute or a suspension containing betahydroxybutyric acid particles.
  • Ketosis refers to a subject having blood ketone levels within the range of about 0.5 mmol/L and about 16 mmol/L. Ketosis may improve mitochondrial function, decrease reactive oxygen species production, reduce inflammation, and increase the activity of neurotrophic factors. “Keto-adaptation” as used herein refers to prolonged nutritional ketosis (>1 week) to achieve a sustained nonpathological “mild ketosis” or “therapeutic ketosis.”
  • “elevated ketone body level” may not mean that a subject is in a state of “clinical ketosis” but nevertheless has an elevated supply of ketones for producing energy and/or for carrying out other beneficial effects of ketone bodies.
  • a subject that is “ketone adapted” may not necessarily have elevated blood serum levels of ketone bodies but rather is able to utilize available ketone bodies more rapidly compared to a subject that is not “ketone adapted.”
  • “elevated ketone body level” can refer to the total quantity and/or rate of ketone bodies being utilized by the subject rather than blood plasma levels per se.
  • Exogenous ketone body refers to beta-hydroxybutyrate and acetoacetate compounds that are not produced by a mammal. These compounds may be utilized by a subject’s body as an energy source during instances of low glucose levels or when these compounds are supplemented in a usable form.
  • Beta-hydroxybutyric acid refers to exogenous beta-hydroxybutyric acid that can be in the form of a powder, other solid, solid particles in a suspension (e.g., sauce or gel), or solute in a solution, such as an aqueous solution.
  • Aqueous beta-hydroxybutyric acid refers to beta-hydroxybutyric acid dissolved in water or other aqueous liquid, in powder or other solid form, or in a gel or other suspension.
  • Beta-hydroxybutyric acid that has self-polymerized to form an insoluble precipitate is not “aqueous beta-hydroxybutyric acid”, although one will appreciate that aqueous beta-hydroxybutyric acid compositions may contain insoluble precipitates without causing harm.
  • a “suspension” means a liquid, syrup, gel, or other non-rigid composition with insufficient water to fully dissolve the beta-hydroxybutyric acid, at least a portion of which remains as undissolved particles surrounded by the suspending liquid, syrup, gel, or other non-rigid composition or carrier.
  • suspending agents include gels, foods, sauces, syrups, oils, and the like.
  • a “gel” refers to a composition that includes a gelling agent, such as a hydrocolloid, and a carrier, such as water or aqueous mixture. Gels can be in the form of a thick liquid, such as a viscous Newtonian fluid, or in the form of a Bingham plastic that does not flow' under the force of gravity but can be deformed by applying pressure or other force.
  • a gelling agent such as a hydrocolloid
  • a carrier such as water or aqueous mixture.
  • Gels can be in the form of a thick liquid, such as a viscous Newtonian fluid, or in the form of a Bingham plastic that does not flow' under the force of gravity but can be deformed by applying pressure or other force.
  • Beta-hydroxybutyric acid compositions may be enriched w'ith or contain enantiomerically pure R-beta-hydroxybutyric acid, enriched with or contain enantiomerically pure S-beta-hydroxybutyric acid, or be provided as a racemic mixture of R- and S-enantiomers.
  • Beta-hydroxybutyric acid compositions specifically those containing a racemic mixture or that are enriched with or contain enantiomerically pure, R-beta-hydroxybutyric acid, are free or substantially free of beta-hydroxybutyrate salts.
  • Beta-hydroxybutyric acid compositions containing more S-beta-hydroxybutyric acid than R-beta-hydroxybutyric acid may be buffered with higher amounts of beta- hydroxybutyrate salt(s) when mixed wdth w-ater.
  • Beia-hydroxybutyric acid compositions may optionally include acetoacetic acid, ester forms of beta- hydroxyb u tyrate and/or acetoacetate, ketone body precursors such as 1,3-butanediol or ester thereof.
  • Beta-hydroxybutyrate is the deprotonated form of beta-hydroxybutyric acid having the formula CH 3 CH 2 OHCH 2 COOH,
  • the deprotonated form present at typical biological pH levels is CH 3 CH 2 OHCH 2 COO
  • the compound When X is a hydrogen, the compound is beta-hydroxybu lyric acid. When X is a metal ion or an amino cation, the compounds is a beta-hydroxybutyrate salt. When X is alkyl, alkenyl, aryl, or acyl, the compounds is a beta-hydroxybutyrate ester.
  • the foregoing compounds can be in any desired physical form, such as crystalline, powder, solid, liquid, solution, suspension, or gel.
  • Acetoacetate is the deprotonated form of acetoacetic acid having the formula CH3COCH 2 COOH.
  • the deprotonated form present at typical biological pH levels is CHsCOCH 2 COO ".
  • the genera! chemical structure of acetoacetate is: where, X can be hydrogen, metal ion, amino cation such as from an amino acid, alkyl, alkenyl, aryl, or acyl.
  • X is a hydrogen
  • the compound is acetoacetic acid.
  • X is a metal ion or an amino cation
  • the compounds is an acetoacetate salt.
  • X is alkyl, alkenyl, aryl, or acyl
  • the compounds is an acetoacetate ester.
  • the foregoing compounds can be in any desired physical form, such as crystalline, powder, solid, liquid, solution, suspension, or gel.
  • salt does not mean or imply any particular physical state, such as a crystalline, powder, other solid form, dissolved in water to form a liquid solution, dispersed in a liquid to form a suspension, or gel.
  • a salt can be formed in solution, such as by at least partially neutralizing beta-hydroxybutyric acid with a strong or weak base, such as an alkali or alkaline earth metal hydroxide, carbonate, or bicarbonate, basic amino acid, and the like.
  • subject or “patient” refers to members of the animal kingdom, including mammals, such as but not limited to, humans and other primates; rodents, fish, reptiles, and birds.
  • the subject may be any animal requiring therapy, treatment, or prophylaxis, or any animal suspected of requiring therapy, treatment, or prophylaxis.
  • Prophylaxis means that regiment is undertaken to prevent a possible occurrence, such as where a high glucose or diabetes is identified. “Patient” and “subject” are used interchangeably herein.
  • Beta-hydroxybutyric acid compositions can include enantiomerically pure R-beta-hydroxybutyric acid, enantiomerically pure S- beta-hydroxybutyric acid, a non- racemic mixture enriched with R-beta-hydroxybutyric acid relative to S-beta- hydroxybutyric acid, a non-racemic mixture enriched with S-beta-hydroxybutvric acid relative to R-beta-hydroxybutyric acid, or a racemic mixture of R- and S-beta- hydroxybutyric acids.
  • beta-hydroxybutyrate free acid, salt, or ester is the R- or S- enantiomer depends on the tetrahedral orientation of the hydroxy on the 3-carbon (betacarbon) in relationship to the planar carboxyl group.
  • R-beta-hydroxybutyrate is the endogenous form of bela-hydroxy butyric acid and can be utilized by a patient’s body as a fuel source during instances of low glucose levels in the subject or when a patient’s body is supplemented with a usable form of beta-hydroxybutyrate.
  • S-beta- hydroxybutyrate is not endogenously produced by mammals but can promote one or more of: increased endogenous production of R-beta-hydroxybutyrate and acetoacetate; endogenous conversion into one or both of R-beta-hydroxybutyrate and acetoacetate; endogenous conversion into fatty’ acids and sterols; prolonged ketosis; direct metabolism of S-beta-hydroxybutyrate; improved fetal development; increased growth years; reduced endogenous production of acetone during ketosis; signaling to modulate metabolism of R-beta-hydroxybutyrate and glucose; antioxidant activity; and production of acetyl-CoA.
  • unit dose refers to a dosage form that is configured to orally deliver a specified quantity or dose of beta-hydroxybutyric acid.
  • Example dosage forms of beta-hydroxybuty’ric acid include, but are not limited to, drinks (such as flavored, vitamin fortified, alcoholic, or non-alcoholic) in premeasured form, such as a can. bottle, carton, jug, and the like, drink additives, liquid energy shots, energy gel packs, foods, food additives, dietetically acceptable sprays (such as flavored mouth spray), and premeasured quantity of powder, solid, or gel, such as packets, pouches, tablets, capsules, efferv escent tablets, and the like.
  • Such dosage forms may be configured to provide a full unit dose or fraction thereof (e.g., 1/2, 1/3, or 1/4 of a unit dose).
  • Another dosage form that can be used to provide a unit dose of betahydroxybutyric acid is a unit dose measuring device, such as a cup, scoop, syringe, dropper, spoon, spatula, or ladle, which is configured to hold therein a measured quantity of composition equaling a full unit dose or fraction thereof (e.g., 1/2, 1/3, or 1/4 of a unit dose).
  • a unit dose measuring device such as a cup, scoop, syringe, dropper, spoon, spatula, or ladle, which is configured to hold therein a measured quantity of composition equaling a full unit dose or fraction thereof (e.g., 1/2, 1/3, or 1/4 of a unit dose).
  • a bulk container such as a carton, box, can, jar, bag, pouch, bottle, jug, or keg, containing several unit doses of composition (e.g., 5-250 or 10-150 unit doses) can be provided to a user together wdth a unit dose measuring device that is configured to provide a unit dose, or fraction thereof, of composition or component thereof.
  • a kit for use in providing beta-hydroxybutyric acid as disclosed herein in bulk form, while providing unit doses of the composition may comprise a bulk container holding therein a quantity of composition and a unit dose measuring device configured to provide a unit dose, or fraction thereof, of composition or component thereof.
  • One or more unit dose measuring devices may be positioned inside the bulk container at the time of sale, attached to the outside of the bulk container, prepackaged with the bulk container within a larger package, or provided by the seller or manufacture for use with one or multiple bulk containers.
  • a bulk container may contain liquid or solid forms of beta-hydroxybutyric acid.
  • the kit may include instructions regarding the size of the unit dose, or fraction thereof, and the manner and frequency of administration.
  • the instructions may be provided on the bulk container, prepackaged with the bulk container, placed on packaging material sold wdth the bulk container, or otherwise provided by the seller or manufacturer (e.g., on websites, mailers, flyers, product literature, etc.)
  • the instructions for use may include a reference on how' to use the unit dose measuring device to properly deliver a unit dose or fraction thereof.
  • the instructions may additionally or alternatively include a reference to common unit dose measuring devices, such as cups, scoops, syringes, droppers, spoons, spatulas, ladles, and the like, not provided with the bulk container (e.g., in case the provided unit dose measuring device is lost or misplaced).
  • a kit may be constructed by the end user when following instructions provided on or with the bulk container, or otherwise provided by the seller regarding the product and how to properly deliver a unit dose of composition, or fraction thereof.
  • the container includes a quantity of tablets or capsules, such as effervescent tablets, each of which includes a premeasured quantity of betahydroxybutyric acid as a full or fractional dose.
  • Capsules or tablets may further be grouped or contained within individual packets or pouches within the storage container, each containing a plurality of tablets or capsules that provide a pre-measured dosage of beta- hydroxybutyric acid.
  • the term “administration” or “administering” is used herein to describe the process in which the aqueous beta-hydroxybutyric acid compositions are orally delivered to a subject.
  • the aqueous beta-hydroxybutyric acid compositions may be combined with a nutritionally or pharmaceutically acceptable carrier or additive.
  • beta-hydroxybutyric acid in the form of an aqueous solution, readily digestible gel or suspension, provides a source of readily usable ketone bodies for producing metabolic energy. This is true regardless of whether the user is technically in state of ketosis. The body is able to metabolize both glucose and ketone bodies when present. If a sufficient quantity of beta-hydroxybutyric acid is consumed in a given time period, it can result in elevated and/or sustained blood levels of ketone bodies, thereby exploiting the metabolic and physiological advantages of ketosis without introducing a significant quantity of electrolytes into the blood.
  • Raising ketone body level in the blood using exogenous ketones provides a subject with greater flexibility in diet options as compared to a method that aims to induce and sustain ketosis based on diet alone (e.g., based on fasting and/or limited carbohydrate intake).
  • a subject that consumes an appropriate amount of beta-hydroxybutyric acid can eat an occasional carbohydrate or sugar-based food without jeopardizing the ketogenic state and shifting back into a glucose-based metabolic state.
  • administration of exogenous beta-hydroxybutyric acid facilitates easier transition to a ketogenic state while reducing or eliminating detrimental effects typically associated with entering ketosis.
  • Subjects entering or maintaining a ketogenic state may already be in a state of electrolyte imbalance due to metabolic shifts involved with ketosis, including enhanced diuretic effects and changes in insulin profiles.
  • the resulting electrolyte imbalance when administering an excessive quantity and/or imbalanced ratio of salts and its associated detrimental physiological effects can offset the benefits of ketosis and/or make it more difficult for a subject to maintain ketosis at the desired levels or for a desired length of time.
  • a formulation containing high levels and/or proportions of sodium beta-hydroxybutyrate can sharply increase sodium level in the subject.
  • Excessive sodium can have detrimental effects, such as hypertension and poor cardiovascular health.
  • High levels of sodium relative to potassium promotes hypertension and increases the risk of cardiovascular disease.
  • a formulation containing high levels and/or proportions of calcium beta-hydroxybutyrate can sharply increase calcium level in the subject.
  • Excessive calcium can build up in soft tissues, leading to detrimental calcification and hardening of such tissues and raising the risk of heart disease (e.g., associated with hardened arteries), kidney stones, arthritis, and other problematic conditions.
  • Aqueous beta-hydroxybutyric acid solutions, gels, and readily digestible suspensions provide a therapeutically effective amount of beta-hydroxybutyrate in the acid, and therefore most readily available form, without contributing significant or any salts.
  • Such compositions provide the advantages of promoting, initiating, and/or sustaining ketosis without significantly altering electrolyte balance in the user, and in some cases even improving or easing electrolyte imbalances.
  • aqueous beta-hydroxybutyric acid compositions for oral delivery that are free or substantially free of beta-hydroxybutyrate salts are effective in rapidly raising blood ketone levels without causing acute acidosis or gastrointestinal (GI) distress when consumed in sufficiently dilute form.
  • GI gastrointestinal
  • aqueous beta-hydroxybutyric acid solutions can deliver exogenous ketone bodies without significantly altering electrolyte balance.
  • aqueous betahydroxybutyric acid can have a concentration that is sufficiently diluted such that volumes in a range of about 4 oz. (about 120 ml) to about 16 oz.
  • dilute aqueous beta-hydroxybutyric acid solutions can have a concentration of beta-hydroxybutyric acid in a range of about 0.4% w/v to about 6% w/v, or about 0.6% w/v to about 5.5% w/v, or about 0.9% w/v to about 5% w/v, or about 1.2% w/v to about 4.5% w/v, or about 1.5% w/v to about 4% w/v.
  • aqueous beta-hydroxybutyric acid solutions are moderately acidic, with a pH of about 3.5 to 4, when diluted with sufficient water, the water itself acts as a pseudo buffering agent that offsets the otherwise harsh effects of the acid when consumed orally.
  • aqueous beta-hydroxybutyric acid solutions can be provided as a concentrate for later dilution by the user, such as with water, juice, drink, energy shot, or other aqueous composition to a concentration in a range of about 0.4% w/v to about 6% w/v, or about 0.6% w/v to about 5.5% w/v, or about 0.9% w/v to about 5% w/v, or about 1.2% w/v to about 4.5% w/v, or about 1.5% w/v to about 4% w/v.
  • Concentrated solutions may comprise beta-hydroxybutyric acid in a range of about 6% w/v to about 60% w/v, or about 8% w/v to about 55% w/v, or about 10% w/v to about 50% w/v, or about 12.5% w/v to about 45% w/v, or about 15% w/v to about 40% w/v, and then diluted by the user as desired, such as from about 2 to about 30 times, or about 3 to about 25 times, or about 4 to about 2 times, or about 5 to about 15 times, with water, juice, drink, or other aqueous composition, as desired.
  • the aqueous beta-hydroxybutyric acid solutions will not be so concentrated that they will self- polymerize and form significant amounts of precipitates, although it should be understood that such polymerized precipitates are harmless and some may be rehydrolyzed in acidic solutions, perhaps under certain conditions in the stomach when consumed with sufficient water.
  • Beta-hydroxybutyric acid compositions are free or substantially free of beta- hydroxybutyrate salts so as to contain less than 1%, or less than 0.9%, or less than 0.8%, or less than 0.7%, or less than 0.6%, or less than 0.5%, or less than 0.4%, or less than 0.3%, or less than 0.2%, or less than 0.1% of one or more beta-hydroxybutyrate salts by combined 'weight of beta-hydroxybutyric acid and beta-hydroxybutyrate salt(s).
  • Beta-hydroxybutyric acid compositions can be essentially or totally free of betahydroxybutyrate salts, i.e., contain 0% by weight of beta-hydroxybutyrate salts.
  • beta-hydroxybutyric acid compositions may contain one or more nutritionally or pharmaceutically acceptable carriers or additives.
  • beta-hydroxybutyric acid compositions may optionally include at least one additive selected from acetoacetic acid, ethanol, glycerin, propylene glycol, 1,3- butanediol, gelling agents (e.g., gellan gum, pectin, agar, carrageenan, xanthan gum, alginate, starch, modified starch, gum Arabic, guar gum, locust bean gum, konjac maanan, gum tragacanth, acacia gum, gum karaya, methyl cellulose, agar, pullulan, konjac, hydroxypropylmethyl cellulose, other cellulosic compounds, other polysaccharide gums, gelatin, collagen, casein, other proteins, silica fume, milled chia seeds, and other hydrocolloids), effervescing agents
  • gelling agents e.g
  • the betahydroxybutyric acid composition may include flavoring agents, such as essential oils, e.g., peppermint, spearmint, Wintergreen, or citrus oils, natural and artificial sweeteners, and other flavorants known in the art.
  • flavoring agents such as essential oils, e.g., peppermint, spearmint, Wintergreen, or citrus oils, natural and artificial sweeteners, and other flavorants known in the art.
  • concentrated or dilute beta-hydroxybutyric acid solutions, gels, sauces, and other compositions can be manufactured by combining a powder or other solid form of beta-hydroxybutyric acid with water, drink, beverage, sauce, gel, or other liquid or semi-liquid drink or food product.
  • the powder or other solid form of beta-hydroxybutyric acid will advantageously include a flavoring agent and may contain other additives, such as one or more of stabilizer (e.g., edible acids, silica, starch, and the like), effervescing agents (e.g., bicarbonate, carbonate, and optionally another acid), vitamin, mineral, stimulant, nootropic, vasodilator, cannabinoid, amino acid, and the like.
  • stabilizer e.g., edible acids, silica, starch, and the like
  • effervescing agents e.g., bicarbonate, carbonate, and optionally another acid
  • vitamin, mineral, stimulant, nootropic, vasodilator, cannabinoid, amino acid, and the like e.g., cannabinoid, amino acid, and the like.
  • the powder, other solid, or gel may be provided in individual pre-dosed packets, pouches, tablets, or capsules, or it may be provided in
  • a plurality (e.g., 2 or 3) of dissolvable tablets representing a single dose can be packaged together in a packet, pouch, or other container.
  • a dissolvable tablet may be effervescent and fizz when added to water.
  • an effervescent tablet it may be desirable to include a quantity of an edible acid (e.g., citric, malic, fumaric, lactic, tartaric, malonic, succinic, adipic, folic, or butyric) together with a bicarbonate salt to provide the desired effervescent action yet provide less than 1% of total beta- hydroxybutyrate salt(s) upon dissolution in water (i.e., if the edible acid has a lower pKa than beta-hydroxybutyric acid a salt of the edible acid will form preferentially over beta -hydroxy butyrate salt).
  • an edible acid e.g., citric, malic, fumaric, lactic, tartaric, malonic, succinic, adipic, folic, or butyric
  • beta-hydroxybutyric acid compositions may include enantiomerically pure R-beta-hydroxybutyric acid, a racemic mixture of R- and S-beta-hydroxybutyric acid (i.e., a mixture having a 1:1 ratio of R-beta-hydroxybutyric acid and S-beta-hydroxybutyric acid enantiomers), a non-racemic mixture enriched with the R-enantiomer, or a non-racemic mixture enriched with the S-enantiomer.
  • beta-hydroxybutyric acid compositions contain a non-racemic mixture enriched with the R-enantiomer, such as greater than 50% and less than 100% by enantiomeric equivalents of exogenous R-beta-hydroxybutyric acid and less than 50% and greater than 0% by enantiomeric equivalents of exogenous S- beta-hydroxybutyric acid.
  • a non-racemic mixture of R- and S- beta-hydroxybutyric acid forms contain 50.1% to 99.9%, 50.2% to 99.8%, 50.3% to 99.7%, 50.4% to 99.6%, 50.5% to 99.5%, 51% to 99%, 52% to 98%, 53% to 97%, 54% to 96%, 55% to 95%, 57% to 93%, or 60% to 90% by enantiomeric equivalents of R- beta-hydroxybutyric acid and 49.9% to 0.1%, 49.8% to 0.2%, 49.7% to 0.3%, 49.6% to 0.4%, 49.5% to 0.5%, 49% to 1%, 48% to 2%, 47% to 3%, 46% to 4%, 45% to 5%, 43% to 7%, 41% to 15%, or 40% to 10% by enantiomeric equivalents of S-beta- hydroxybutyric acid,
  • beta-hydroxybutyric acid compositions contain a non-racemic mixture enriched with the S-enantiomer, such as greater than 50% and less than 100% by enantiomeric equivalents of exogenous S-beta-hydroxybutyric acid and less than 50% and greater than 0% by enantiomeric equivalents of exogenous R-beta- hydroxybutyric acid.
  • a non-racemic mixture of S- and R-beta- hydroxybutyric acid forms contain 50.1% to 99.9%, 50.2% to 99.8%, 50.3% to 99.7%, 50.4% to 99.6%, 50.5% to 99.5%, 51% to 99%, 52% to 98%, 53% to 97%, 54% to 96%, 55% to 95%, 57% to 93%, or 60% to 90% by enantiomeric equivalents of S-beta- hydroxybutyric acid and 49.9% to 0.1%, 49.8% to 0.2%, 49.7% to 0.3%, 49.6% to 0.4%, 49.5% to 0.5%, 49% to 1%, 48% to 2%, 47% to 3%, 46% to 4%, 45% to 5%, 43% to 7%, 41% to 15%, or 40% to 10% by enantiomeric equivalents of R-beta- hydroxybutyric acid.
  • beta-hydroxybutyric acid compositions contain a racemic (or near racemic) mixture of R-beta-hydroxybutyric acid and S-beta- hydroxybutyric acid, i.e., that contains 50% by enantiomeric equivalents of exogenous R-beta-hydroxybutyric acid and 50% by enantiomeric equivalents of exogenous S-beta- hydroxybutyric acid.
  • a near racemic mixture that is not a perfect 50:50 mixture of R- and S-enantiomers may include about 49.9% to about 50.1%, or about 49.92% to about 50.08%, or about 49.94% to about 50.06%, or about 49.96% to about 50.04%, or about 49.98% to about 50.02%, by enantiomeric equivalents of R-beta-hydroxybutyrate and about 50.1% to about 49.9%, or about 50.06% to about 49.94%, or about 50.04% to about 49.96%, or about 50.02% to about 49.98%, by enantiomeric equivalents of S- beta-hy dr oxybutyrate.
  • beta-hydroxybutyric acid compositions contain enantiomerically pure S-beta-hydroxybutyric acid, i.e., that contains 100% by enantiomeric equivalents of exogenous S-beta-hydroxybutyric acid and 0% by enantiomeric equivalents of R-beta-hydroxybutyric acid.
  • beta-hydroxybutyric acid compositions contain enantiomerically pure R-beta-hydroxybutyric acid, i.e., that contains 100% by enantiomeric equivalents of exogenous R-beta-hydroxybutyric acid and 0% by enantiomeric equivalents of S-beta-hydroxybutyric acid. Because exogenous R-beta- hydroxybutyric acid dissolved in water to form an aqueous solution with a “water buffer” is not found in nature, it is not a “natural product”.
  • R-beta- hydroxybutyric acid and/or R-beta-hydroxybutyrate is produced endogenously and naturally by mammals so as to be a natural product.
  • the endogenous form of beta-hydroxybutyric acid only exists as substantially deprotonated R-beta- hydroxybutyrate anions and not in powder or other solid form, concentrated solution, or even dilute aqueous R-beta-hydroxybutyric acid within the disclosed concentrations.
  • S-beta-hydroxybutyric acid which is not endogenously produced by mammals and is believed by some to be unnatural and potentially harmful, can provide other beneficial effects. These include one or more of: increased endogenous production of R-beta-hydroxybutyrate and acetoacetate; endogenous conversion into one or both of R-beta-hydroxybutyrate and acetoacetate; endogenous conversion into fatty acids and sterols; prolonged ketosis; metabolism of S-beta-hydroxybutyrate independent of its conversion to R-beta- hydroxybutyrate and z or acetoacetate; improved fetal development; increased growth years; reduced endogenous production of acetone during ketosis; signaling to modulate metabolism of R-beta-hydroxybutyrate and glucose; antioxidant activity; and production of acetyl-CoA.
  • Beta-hydroxybutyric acid enriched with, or that contains enantiomerically pure, S-beta-hydroxybutyric acid may be administered in higher doses than compositions enriched with, or that contain enantiomerically pure, R-beta- hydroxybutyric acid to obtain the same rapid supply of R-beta-hydroxybutyrate in the body.
  • beta-hydroxybutyrate salts such as less than 4.0%, or less than 3.75%, or less than 3.5%, or less than 3.25%, or less than 3.0%, or less than 2.75%, or less than 2.5% or less than 2.25%, or less than 2%, or less than 1.75%, or less than 1.5%, or less than 1.25%, of such salts by combined weight of beta-hydroxybutyric acid and beta- hydroxybutyrate salt(s), in order to further offset the greater acidity of higher concentrations and/or amounts of beta-hydroxybutyric acid in compositions that are enriched with, or contain enantiomerically pure, S-beta-hydroxybutyric acid.
  • beta-hydroxybutyrate salts such as less than 4.0%, or less than 3.75%, or less than 3.5%, or less than 3.25%, or less than 3.0%, or less than 2.75%, or less than 2.5% or less than 2.25%, or less than 2%, or less than 1.75%, or less than 1.5%, or less than
  • beta-hydroxybutyric acid compositions may optionally include beta-hydroxybutyrate salts in which the cations are provided by an amino acid or other organic compound having a net positive charge at acidic pH.
  • beta- hydroxybutyrate-amino acid compounds can provide a soluble form of beta- hydroxybutyrate without providing electrolytes such as sodium, potassium, calcium or magnesium.
  • Most amino acids have a net positive charge at acidic pH. Examples include arginine, lysine, leucine, iso-leucine, histidine, ornithine, citrulline, glutamine, or other suitable amino acids or metabolites of amino acids (e.g., creatine).
  • Some amino acids also provide health benefits. For example, arginine and citrulline can increase nitric oxide in the blood, which dilates blood vessels and improves blood circulation for persons with heart conditions (and may help men suffering from erectile dysfunction).
  • beta-hydroxybutyric acid compositions can be provided as an aqueous solution, such as in the form of a beverage, a concentrated energy shot, or mouth spray for fast delivery and absorption.
  • Beta-hydroxybutyric acid compositions can be provided as gel, such as an energy gel.
  • Beta-hydroxybutyric acid compositions can be provided as a food product, such as a sauce or condiment.
  • Betahydroxybutyric acid compositions can be provided as a powder or other solid that can be added to water, drink or food to form an ingestible aqueous solution, gel or suspension.
  • beta-hydroxybutyric acid compositions may optionally include other liquid carriers, such as water, ethanol, glycerin, propylene glycol, 1,3- propandiol, and the like.
  • the compositions may include vitamins and/or minerals.
  • Other additives include metabolites that enhance the effect or transport of ketone bodies into mitochondria, caffeine, theobromine, and nootropics, such as L-alpha glycerylphosphorylcholine (“alpha GPC”).
  • the compositions may include flavoring agents, such as essential oils, e.g., peppermint, spearmint, wintergreen, or citrus oils, natural and artificial sweeteners, and other flavorants known in the art.
  • Beta-hydroxybutyric acid compositions can optionally include one or more beta-hydroxybutyrate esters.
  • Example beta-hydroxybutyrate esters include mono-, di-, tri-, oligo-, and polyesters. Examples include mono-ester of ethanol, mono-ester of 1- propanol, mono-ester of 1 ,2-propanediol, di-ester of 1,2-propanediol, mono-ester of 1,3-propanediol, di-ester of 1 ,3-propanediol, mono- or di-ester of S-, R-, or S-R-1,3- butanediol, mono-, di-, or tri-ester of glycerin, ester of acetoacetate, dimers, trimers, oligomers, and polyesters containing repeating units of beta-hydroxybutyrate, and complex oligomers or polymers of beta-hydroxybutyrate and one or more other hydroxy-carboxy
  • Beta-hydroxybutyric acid compositions may optionally include short-, medium, and''or long-chain fatty acids and/or esters thereof. Most of such components can have limited solubility in water and may require use of emulsifier and/or remain as particles in suspension, while water soluble forms, particularly short chain fatty acids, have a very strong taste.
  • Short chain fatty' acids contain 2 to 5 carbon atoms and include acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, and isovaleric acid.
  • Medium chain fatty acids contain from 6 to 12 carbons and include caproic acid, caprylic acid, capric acid, and lauric acid.
  • Long chain fatty acids contain more than 12 carbon atoms and include myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, cerotic acid, omega-3 fatty acids, omega-6 fatty acids, omega-7 fatty acids, and omega-9 fatty acids.
  • aqueous beta- hydroxybutyric acid compositions are substantially free of short-, medium-, and long- chain fatty' acids and esters thereof, such as less than 5%, 4%, 3%, 2%, or 1%.
  • Beta-hydroxybutyric acid compositions can be used in a method for increasing ketone body level, including promoting and/or sustaining ketosis, in a subject comprising administering to a subject in need thereof a nutritionally or pharmaceutically effective amount of beta-hydroxybutyric acid.
  • beneficial effects of increasing ketone body level, including promoting and/or sustaining ketosis, in a subject include one or more of appetite suppression, weight loss, fat loss, reduced blood glucose level, improved mental alertness, increased physical energy, improved cognitive function, reduction in traumatic brain injury, reduction in effect of diabetes, improvement of neurological disorder, reduction of cancer, reduction of inflammation, anti-aging, antiglycation, reduction in epileptic seizer, improved mood, increased strength, increased muscle mass, or improved body composition.
  • Beta-hydroxybutyric acid can be administered to a subject in therapeutically effective dosages and/or in frequencies to induce or sustain ketosis.
  • a single dose may provide from about 0.5 gram to about 25 grams, or about 0.75 gram to about 20 grams, or about 1 gram to about 15 grams, or about 1.5 grams to about 12 grams, or about 2 grams to about 10 grams of combined weight of beta-hydroxybutyric acid and beta-hydroxybutyrate compounds.
  • Beta-hydroxybutyric acid compositions can include or be administered together with other supplements, such as vitamin Ds, vitamins, minerals, nootropics, and others known in the art.
  • vitamins, minerals and herbal supplements that can be added to the ketogenic compositions include one or more of vitamin A, vitamin C, vitamin E, niacin, vitamin B6, folic acid, 5-MTHF, vitamin BI2, iodine, zinc, copper, manganese, chromium, caffeine, theobromine, theacrine, methylliberine, huperzine A, epicatechins, and enzymes.
  • the subject may follow a ketogenic diet that restricts intake of carbohydrates and protein during the period of administration.
  • the subject may restrict the dietary intake to a ratio of about 65% fat, about 25% protein, and about 10% carbohydrates.
  • the resulting therapeutic ketosis provides a rapid and sustained keto-adaptation as a metabolic therapy for a wide range of metabolic disorders, and provides nutritional support for therapeutic fasting, weight loss, and performance enhancement.
  • the composition is typically administered once per day, twice per day, or three times per day to a subject desiring to promote and/or sustain a state of ketosis.
  • multiple doses of the composition are administered over time.
  • the frequency of administration of the composition can vary depending on any of a variety of factors, such as timing of treatment from previous treatments, objectives of the treatment, and the like.
  • the duration of administration of the composition (e.g., the time period over which the agent is administered), can vary depending on any of a variety of factors, including subject response, desired effect of treatment, etc.
  • the amount of the composition to be administered can vary according to factors such as the degree of susceptibility of the individual, the age, sex, and weight of the individual, idiosyncratic responses of the individual, and the like.
  • the “therapeutically effective amount” is that amount necessary' to promote a therapeutically effective result in vivo (i.e., therapeutic ketosis).
  • a suitable single dose size is a dose that is capable of preventing or alleviating (reducing or eliminating) a symptom in a patient when administered one or more times over a suitable time period.
  • composition administered will depend on potency, absorption, distribution, metabolism, and excretion rates of unused ketone bodies, electrolytes, the method of administration, and the particular disorder being treated, as well as other factors known to those of skill in the art.
  • the dose should be sufficient to affect a desirable response, such as a therapeutic or prophylactic response against a particular disorder or condition, taking into account the severity of the condition to be alleviated.
  • the aqueous beta-hydroxybutyric acid solution may be administered once, or may be divided and administered over intervals of time. It is to be understood that administration may be adjusted according to individual need and professional judgment of a person administrating or supervising the administration of the compositi ons. IV. Examples
  • An aqueous beta-hydroxybutyric acid solution is prepared by mixing beta- hydroxybutyric acid (e.g., powder or other solid form) with water to form a highly concentrated solution containing 60% w/v of beta-hydroxybutyric acid.
  • the concentrated aqueous beta-hydroxybutyric acid solution is readily administered as a ketogenic composition by mixing with 10 to 30 parts of water, juice, beverage, or other aqueous composition.
  • An aqueous beta-hydroxybutyric acid solution is prepared by mixing betahydroxybutyric acid (e.g., powder or other solid form) with water to form a highly concentrated solution containing 50% w/v of beta-hydroxybutyric acid.
  • the concentrated aqueous beta-hydroxybutyric acid solution is readily administered as a ketogenic composition by mixing with 9 to 28 parts of water, juice, beverage, or other aqueous composition.
  • An aqueous beta-hydroxybutyric acid solution is prepared by mixing betahydroxybutyric acid (e.g., powder or other solid form or more concentrated solution) with water to form a less highly concentrated solution containing 40% w/v of betahydroxybutyric acid.
  • betahydroxybutyric acid e.g., powder or other solid form or more concentrated solution
  • the concentrated aqueous beta-hydroxybutyric acid solution is readily administered as a ketogenic composition by mixing with 8 to 25 parts of water, juice, beverage, or other aqueous composition.
  • Example 4 An aqueous beta-hydroxybutyric acid solution is prepared by mixing betahydroxybutyric acid (e.g., powder or other solid form or more concentrated solution) with water to form a less highly concentrated solution containing 35% w/v of betahydroxybutyric acid.
  • the concentrated aqueous beta-hydroxybutyric acid solution is readily administered as a ketogenic composition by mixing with 7 to 22 parts of water, juice, beverage, or other aqueous composition.
  • An aqueous beta-hydroxybutyric acid solution is prepared by mixing betahydroxybutyric acid (e.g., powder or other solid form or more concentrated solution) with water to form a moderately concentrated solution containing 30% w/v of beta- hydroxybutyric acid.
  • betahydroxybutyric acid e.g., powder or other solid form or more concentrated solution
  • the concentrated aqueous beta-hydroxybutyric acid solution is readily administered as a ketogenic composition by mixing with 6 to 18 parts of water, juice, beverage, or other aqueous composition.
  • Example 6 An aqueous beta-hydroxybutyric acid solution is prepared by mixing betahydroxybutyric acid (e.g., powder or other solid form or more concentrated solution) with water to form a moderately concentrated solution containing 25% w/v of betahydroxybutyric acid.
  • the concentrated aqueous beta-hydroxybutyric acid solution is readily administered as a ketogenic composition by mixing with 5 to 15 parts of water, juice, beverage, or other aqueous composition.
  • An aqueous beta-hydroxybutyric acid solution is prepared by mixing betahydroxybutyric acid (e.g., powder or other solid form or more concentrated solution) with water to form a moderately concentrated solution containing 20% w/v of beta- hydroxybutyric acid.
  • betahydroxybutyric acid e.g., powder or other solid form or more concentrated solution
  • the concentrated aqueous beta-hydroxybutyric acid solution is readily administered as a ketogenic composition by mixing with 4 to 12 parts of water, juice, beverage, or other aqueous composition.
  • An aqueous beta-hydroxybutyric acid solution is prepared by mixing beta- hydroxybutyric acid (e.g., powder or other solid form or more concentrated solution) with water to form a fairly concentrated solution containing 15% w/v of betahydroxybutyric acid.
  • the concentrated aqueous beta-hydroxybutyric acid solution is readily administered as a ketogenic composition by mixing with 3 to 9 parts of water, juice, beverage, or other aqueous composition.
  • An aqueous beta-hydroxybutyric acid solution is prepared by mixing betahydroxybutyric acid (e.g., powder or other solid form or more concentrated solution) with water to form a fairly concentrated solution containing 10% w/v of betahydroxybutyric acid.
  • the concentrated aqueous beta-hydroxybutyric acid solution is readily administered as a ketogenic composition by mixing wdth 2 to 8 parts of water, juice, beverage, or other aqueous composition.
  • An aqueous beta-hydroxybutyric acid solution is prepared by mixing beta- hydroxybutyric acid (e.g., powder or other solid form or more concentrated solution) with water to form a fairly dilute solution containing 6% w/v of beta-hydroxybutyric acid.
  • the aqueous beta-hydroxybutyric acid solution can be used as is or mixed with another substance.
  • Example 11 An aqueous beta-hydroxybutyric acid solution is prepared by mixing betahydroxybutyric acid (e.g., powder or other solid form or more concentrated solution) with water to form a fairly dilute solution containing 5% w/v of beta-hydroxybutyric acid.
  • the aqueous beta-hydroxybutyric acid solution can be used as is or mixed with another substance.
  • Example 12
  • An aqueous beta-hydroxybutyric acid solution is prepared by mixing betahydroxybutyric acid (e.g., powder or other solid form or more concentrated solution) with water to form a moderately dilute solution containing 4% w/v of betahydroxybutyric acid.
  • betahydroxybutyric acid e.g., powder or other solid form or more concentrated solution
  • the aqueous beta-hydroxybutyric acid solution can be used as is or mixed with another substance.
  • An aqueous beta-hydroxybutyric acid solution is prepared by mixing betahydroxybutyric acid (e.g., powder or other solid form or more concentrated solution) with water to form a more dilute solution containing 3% w/v of beta-hydroxybutyric acid.
  • betahydroxybutyric acid e.g., powder or other solid form or more concentrated solution
  • the aqueous beta-hydroxybutyric acid solution can be used as is or mixed with another substance.
  • An aqueous beta-hydroxybutyric acid solution is prepared by mixing betahydroxybutyric acid (e.g., powder or other solid form or more concentrated solution) with water to form an even more dilute solution containing 2% w7v of betahydroxybutyric acid.
  • betahydroxybutyric acid e.g., powder or other solid form or more concentrated solution
  • the aqueous beta-hydroxybutyric acid solution can be used as is or mixed with another substance.
  • An aqueous beta-hydroxybutyric acid solution is prepared by mixing beta- hydroxybutyric acid (e.g., powder or other solid form or more concentrated solution) with water to form a very dilute solution containing 1.5% w/v of beta-hydroxybutyric acid.
  • the aqueous beta-hydroxybutyric acid solution can be used as is or mixed with another substance.
  • An aqueous beta-hydroxybu lyric acid solution is prepared by mixing betahydroxybutyric acid (e.g., powder or other solid form or more concentrated solution) with water to form a highly dilute solution containing 1% w/v of beta-hydroxybutyric acid.
  • betahydroxybutyric acid e.g., powder or other solid form or more concentrated solution
  • the aqueous beta-hydroxybutyric acid solution can be used as is or mixed with another substance.
  • aqueous beta-hydroxybutyric acid solutions is modified by including a gelling agent to form a gel.
  • the gelling agent can be one or more of gellan gum, pectin, agar, carrageenan, xanthan gum, alginate, starch, modified starch, gum Arabic, guar gum, locust bean gum, konjac maanan, gum tragacanth, acacia gum, gum karaya, methyl cellulose, agar, pullulan, konjac, hydroxypropylmethyl cellulose, other cellulosic compounds, other polysaccharide gums, gelatin, collagen, casein, other proteins, silica fume, milled chia seeds, and other hydrocolloids.
  • the gelling agent is included in an amount to yield a gel of desired consistency, such as a viscous Newtonian fluid or a Bingham plastic.
  • beta-hydroxybutyric acid solutions or gels include other carrier materials in which beta-hydroxybutyric acid is insoluble or less soluble in order to form a suspension containing particles of beta-hydroxybutyric acid.
  • the quantity of water is reduced to be less than the amount required to dissolve the beta-hydroxybutyric acid.
  • the suspension can be a liquid, a gel, a sauce, or other food or drink material.
  • Example 19 Any of the foregoing beta-hydroxybutyric acid compositions is combined with one or more short chain fatty' acids or ester thereof.
  • beta-hydroxybutyric acid compositions is combined with a beta-hydroxybutyrate compound containing a cationic amino acid selected from arginine, lysine, leucine, iso-leucine, histidine, ornithine, citrulline, L-glutamine, or metabolite of an amino acid, such as creatine).
  • a beta-hydroxybutyrate amino acid compound containing a cationic amino acid selected from arginine, lysine, leucine, iso-leucine, histidine, ornithine, citrulline, L-glutamine, or metabolite of an amino acid, such as creatine.
  • the beta-hydroxybutyrate amino acid compound provides an additional source of beta-hydroxybutyrate without adding electrolytes to the composition.
  • any of the foregoing beta-hydroxy butyric acid compositions can include a non-racemic mixture enriched with R-beta-hydroxybutyric acid, which can be prepared by mixing R-beta-hydroxybutyric acid with a racemic mixture of R- and S-beta- hydroxybutyric acids to provide greater than 50% and less than 100% by enantiomeric equivalents of R-beta-hydroxybutyric acid and less than 50% and greater than 0% by enantiomeric equivalents of S-beta-hydroxybutyric acid. Because the non-racemic mixture includes more of the R-enantiomer, the onset of ketosis is accelerated for a given dosage as compared to the same dosage of a racemic mixture. On the other hand, including the S-enantiomer provides for a longer state of ketosis and z or other benefits as disclosed herein compared to using pure R-beta-hydroxybutyric acid.
  • any of the foregoing beta-hydroxybutyric acid compositions can include a non-racemic mixture enriched with S-beta-hydroxybutyric acid, which can be prepared by mixing S-beta-hydroxybutyric acid with a racemic mixture of R- and S-beta- hydroxybutyric acids to provide greater than 50% and less than 100% by enantiomeric equivalents of S-beta-hydroxybutyric acid and less than 50% and greater than 0% by enantiomeric equivalents of R-beta-hydroxybutyric acid. Because the non-racemic mixture includes more of the S-enantiomer, the onset of ketosis is delayed for a given dosage as compared to the same dosage of a racemic mixtur e.
  • any of the foregoing beta-hydroxybutyric acid compositions can include a racemic mixture of R-beta-hydroxybutyric acid and S-beta-hydroxybutyric acid to provide 50% by enantiomeric equivalents of the R-enantiomer and 50% by enantiomeric equivalents of the S-enantiomer. Because the composition contains a racemic mixhire, the onset of ketosis is accelerated for a given dosage as compared to the same dosage enriched with the S-enantiomer. On the other hand, because the racemic mixture includes 50% by enantiomeric equivalents of the S-enantiomer, the duration of sustained ketosis is increased for a given dosage as compared to the same dosage enriched with the R-enantiomer.
  • beta-hydroxybutyric acid compositions is modified byincluding one or more supplements, such as one or more vitamins, minerals, herbs, and others known in the art.
  • supplements such as one or more vitamins, minerals, herbs, and others known in the art.
  • beta-hydroxybutyric acid compositions is modified byincluding one or more beta-hydroxybutyrate esters.
  • any of the foregoing beta-hydroxybutyric acid compositions is modified by including one or more fat burner supplements such as green tea, green tea extract (e.g., a composition including one or more isolated green tea catechins such as epigallocatechin gallate (EGCG)), green coffee extract, conjugated linoleic acid (CEA), tetradecyl thioacetic acid (TTA), Coleus forskohlii (i.e., forskolin), yohimbine, rauwolscine, capsaicin, raspberry ketones (e.g., 4-(4-hydroxyphenyl) butan-2-one, p- hydroxybenzyl acetone), ephedrine, synephrine (e.g., bitter orange extract), octopamine, 1, 3 -dimethyl amylamine, higenamine, fucoxanthin, acetylcholine modulators and/or adenosine receptor antagonists (e.g., EGCG
  • Example 27 Any of the foregoing beta-hydroxybutyric acid compositions is modified by including one or more nootropic supplements such as tyrosine, L-DOPA (i.e., L-3,4- dihydroxyphenylalanine), tryptophan, and 5 -hydroxytryptophan (5-HTP), racetams such as such as piracetam, oxiracetam, and aniracetam, L-theanine, D-serine, phosphatidylserine, tolcapone, uridine, vinpocetine, norepinephrine reuptake inhibitors such as hordenine and atomoxetine.
  • nootropic supplements such as tyrosine, L-DOPA (i.e., L-3,4- dihydroxyphenylalanine), tryptophan, and 5 -hydroxytryptophan (5-HTP)
  • racetams such as such as piracetam, oxiracetam, and aniracetam
  • cAMP cyclic adenosine monophosphate
  • the resulting combined supplement is expected to provide greater cognition, alertness, and/or mood effects than a similar dose that includes only beta- hydroxybutyrate compounds .
  • the present invention may be embodied in oilier specific forms without departing from its spirit or essential characteristics.
  • the described embodiments are to be considered in all respects only as illustrative and not restrictive.
  • the scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

Les compositions d'acide bêta-hydroxybutyrique destinées à être administrées par voie orale sont sensiblement exemptes de sels de bêta-hydroxybutyrate et sont efficaces pour élever rapidement les taux de cétones dans le sang sans provoquer d'acidose aiguë ou de détresse gastro-intestinale (GI) lorsqu'elles sont consommées sous une forme suffisamment diluée et/ou sous la forme d'un gel ou d'une suspension. Grâce à l'exclusion de sels de bêta-hydroxybutyrate (par exemple, moins de 1 % en poids) contenant des ions de métal alcalin ou alcalino-terreux, les solutions, gels ou suspensions d'acide bêta-hydroxybutyrique peuvent administrer des corps cétoniques exogènes sans modifier de façon significative l'équilibre électrolytique. Bien que les solutions d'acide bêta-hydroxybutyrique aqueuses soient modérément acides avec un pH d'environ 3,5 à 4, lorsque lesdites solutions sont diluées avec une quantité d'eau suffisante, l'eau agit comme un pseudo-tampon qui compense autrement les effets acides sévères lorsque lesdites solutions sont consommées par voie orale. Les gels et les suspensions peuvent également améliorer les effets acides grâce à l'encapsulation partielle de l'acide bêta-hydroxybutyrique. L'acide bêta-hydroxybutyrique peut être enrichi avec l'énantiomère R ou l'énantiomère S, un mélange racémique, de l'acide R-bêta-hydroxybutyrique pur ou de l'acide S-bêta-hydroxybutyrique pur.
EP21859286.3A 2020-08-18 2021-09-14 Compositions d'acide bêta-hydroxybutyrique et procédés d'administration orale de corps cétoniques Pending EP4200274A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/996,509 US10973786B2 (en) 2016-03-11 2020-08-18 R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US17/210,646 US11806324B2 (en) 2018-04-18 2021-03-24 Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
PCT/US2021/050302 WO2022040644A2 (fr) 2020-08-18 2021-09-14 Compositions d'acide bêta-hydroxybutyrique et procédés d'administration orale de corps cétoniques

Publications (2)

Publication Number Publication Date
EP4200274A2 true EP4200274A2 (fr) 2023-06-28
EP4200274A4 EP4200274A4 (fr) 2024-10-23

Family

ID=80323202

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21859286.3A Pending EP4200274A4 (fr) 2020-08-18 2021-09-14 Compositions d'acide bêta-hydroxybutyrique et procédés d'administration orale de corps cétoniques

Country Status (3)

Country Link
EP (1) EP4200274A4 (fr)
AU (1) AU2021327408A1 (fr)
WO (1) WO2022040644A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
US20230346699A1 (en) * 2022-04-28 2023-11-02 Axcess Global Sciences, Llc Administration of r-beta-hydroxybutyrate and related compounds in veterinary applications

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5030553B2 (ja) * 2006-11-24 2012-09-19 有限会社ノーベル医学研究所 ドライマウスおよび／または唾液分泌障害を処置するための医薬
WO2011149814A2 (fr) * 2010-05-24 2011-12-01 Amerilab Technologies, Inc. Composition effervescente pour la formation d'une composition gélifiée, comprimé pour la formation d'une composition gélifiée et procédé de fabrication d'une composition gélifiée
US10245242B1 (en) * 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
GB201616058D0 (en) * 2016-09-21 2016-11-02 Chain Biotechnology Ltd Probiotic composition
JP6804352B2 (ja) * 2017-03-22 2020-12-23 大阪瓦斯株式会社 コラゲナーゼｍｍｐ１及び３の産生抑制剤
WO2018187324A1 (fr) * 2017-04-04 2018-10-11 NNB Nutrition USA, LLC Préparation de l'acide (r)-3-hydroxybutyrique ou ses sels par fermentation en une étape
US11760963B2 (en) * 2017-08-23 2023-09-19 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
US10925843B2 (en) * 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11806324B2 (en) * 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
CA3022995C (fr) * 2018-06-12 2019-10-15 Ketofibe (9211-3133 Quebec Inc.) Composes cetogenes novateurs, compositions, methodes et utilisations associees
CA3170624A1 (fr) * 2020-03-05 2021-09-10 VitaNav, Inc. Composition d'acide (d)-?-hydroxybutyrique, d'acide (d)-?-hydroxyvalerique et de (d)-1,3 butanediol en tant que supplement nutritionnel et agent therapeutique
CN112262936A (zh) * 2020-10-22 2021-01-26 珠海麦得发生物科技股份有限公司 一种含3-羟基丁酸的饮品及其制备方法和应用

Also Published As

Publication number Publication date
WO2022040644A3 (fr) 2022-04-07
AU2021327408A1 (en) 2023-04-20
EP4200274A4 (fr) 2024-10-23
WO2022040644A2 (fr) 2022-02-24

Similar Documents

Publication Publication Date Title
US11806324B2 (en) Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US10973786B2 (en) R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US11020362B2 (en) Beta-hydroxybutyrate mixed salt compositions and methods of use
AU2019255182B2 (en) Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
WO2022040644A2 (fr) Compositions d'acide bêta-hydroxybutyrique et procédés d'administration orale de corps cétoniques
US10973792B2 (en) Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
JP7448555B2 (ja) ラセミベータ－ヒドロキシブチレート混合塩－酸組成物および使用方法
US20220062216A1 (en) Compositions and methods for increasing lean-to-fat mass ratio
JP2023166029A (ja) ベータ－ヒドロキシブチレート混合塩－酸組成物およびキット
US20230201145A1 (en) Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
CA3166226C (fr) Compositions de sel-acide mixtes de r-beta-hydroxybutyrate enantiomeriquement pur
US20230346721A1 (en) Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
CA3192343A1 (fr) Compositions d'acide beta-hydroxybutyrique et procedes d'administration orale de corps cetoniques
US11419836B2 (en) Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
JP2022520204A (ja) Ｓ－ベータ－ヒドロキシブチレート化合物およびｓ－エナンチオマー富化組成物

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230303

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07C0059010000

Ipc: A61K0031190000